Signal transduction modulators for cancer therapy: from promise to practice?

Oncologist. 2003;8(2):210-3. doi: 10.1634/theoncologist.8-2-210.
No abstract available

Publication types

  • Guideline
  • Practice Guideline

MeSH terms

  • Antineoplastic Agents / standards
  • Antineoplastic Agents / therapeutic use
  • Clinical Trials as Topic
  • Enzyme Inhibitors / standards
  • Enzyme Inhibitors / therapeutic use
  • ErbB Receptors / drug effects
  • Gefitinib
  • Health Knowledge, Attitudes, Practice
  • Humans
  • Neoplasms / drug therapy*
  • Neoplasms / physiopathology*
  • Quinazolines / standards
  • Quinazolines / therapeutic use
  • Signal Transduction / drug effects*
  • Signal Transduction / physiology*
  • United States
  • Vascular Endothelial Growth Factor Receptor-2 / drug effects

Substances

  • Antineoplastic Agents
  • Enzyme Inhibitors
  • Quinazolines
  • ErbB Receptors
  • Vascular Endothelial Growth Factor Receptor-2
  • Gefitinib